Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma

NCT03546166 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma

Interventions

DRUG: Picato 0.05% Topical Gel

Sponsor

Centre Hospitalier Universitaire de Nice